news
FDA-approved cancer drug doses may be too high, researchers say
A Kaiser Health News investigation reveals patients and researchers believe many cancer drug dosages, including immunotherapies like Keytruda and Opdivo, are excessive. Reducing these amounts could save billions and lessen severe side effects. This isn't about whether the drugs work, but about how much of them we actually need to get the benefit without the brutal cost to the body.
A Kaiser Health News investigation reveals patients and researchers believe many cancer drug dosages, including immunotherapies like Keytruda and Opdivo, are excessive. Reducing these amounts could save billions and lessen severe side effects. This isn't about whether the drugs work, but about how much of them we actually need to get the benefit without the brutal cost to the body.
The architecture take
I'm always watching for news that flips the script on conventional wisdom, especially when it comes to medicine. This isn't some fringe idea; we're talking about KFF reporting that patients and even oncologists are questioning FDA-approved dosing. The claim is that current cancer drug levels are often higher than necessary, leading to worse side effects and burning through billions more in healthcare costs. Think about the cumulative load on the body: if you're taking more than you need, your system is just trying to process the excess, often leading to brutal fatigue, nausea, and neuropathy that compounds the original illness. It’s a gut punch to the nervous system. The push is to get regulatory bodies to look at real-world data and consider lower, more sustainable doses. I mean, if the same efficacy can be had with less, why aren't we doing it? Follow the money, I guess. What this points to is a bigger pattern of 'more is better' in medicine, which isn't always true for your body or your bank account.